Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00789828 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Everolimus (RAD001) in Patients of All Ages With Subependymal Giant Cell Astrocytoma Associated With Tuberous Sclerosis Complex (TSC)(EXIST-1)
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 117
- Enrollment target
NCT00789828 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 117 participants.
The verdict
NCT00789828, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 117 participants
- Enrollment target
Study Summary
This study evaluated the efficacy and safety of Everolimus in treating patients with Subependymal Giant Cell Astrocytomas associated with Tuberous Sclerosis Complex.
Interventions
- DRUG Placebo
- DRUG Everolimus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 117 participants |
| Start Date | 2009-08 |
| Est. Completion | 2014-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00789828
The ClinicalTrials.gov registry entry for NCT00789828 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 117 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00789828 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00789828 about?
NCT00789828 is a clinical study titled "Efficacy and Safety of Everolimus (RAD001) in Patients of All Ages With Subependymal Giant Cell Astrocytoma Associated With Tuberous Sclerosis Complex (TSC)(EXIST-1)". This study evaluated the efficacy and safety of Everolimus in treating patients with Subependymal Giant Cell Astrocytomas associated with Tuberous Sclerosis Complex.
What is the current status of trial NCT00789828?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 117 participants. The study started on 2009-08. Estimated completion is 2014-10.
What interventions are being tested in trial NCT00789828?
The interventions under investigation include: Placebo (DRUG), Everolimus (DRUG).
Who is sponsoring clinical trial NCT00789828?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.